
    
      This was a Phase 3, randomized, double-blind, placebo-controlled, parallel-group multicenter
      study of orally administered lumacaftor in combination with ivacaftor in participants aged 12
      years and older with CF who are homozygous for the F508del-CFTR mutation.

      The study included a Screening Period (Day -28 through Day -1), a Treatment Period (Day 1
      [first dose of study drug] to Week 24 ± 5 days), and a Safety Follow-up Visit (4 weeks ± 7
      days after the Week 24 Visit).
    
  